Renibus Therapeutics

Executive Summary

Renibus Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies that prevent disease progression and protect against organ damage in cardiorenal diseases. Founded in 2018 and headquartered in Southlake, Texas, the company is advancing a lead candidate in Phase 3 clinical trials targeting cardiorenal protection, potentially addressing large unmet needs in acute kidney injury (AKI) and heart failure with renal dysfunction. Renibus's approach aims to improve patient outcomes and extend life by mitigating the interplay between cardiac and renal systems. As a private company, it has not disclosed total funding or valuation, but its Phase 3 status suggests significant investor support and a clear path toward regulatory milestones. The company's pipeline remains undisclosed, but its focus on dual organ protection positions it as a promising player in the cardiorenal space.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout for Lead Candidate55% success
• Q2 2026Potential Partnership or Licensing Deal40% success